# TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Source: https://onco.cc/trials/nct07047365/  
OnCo record `nct07047365` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of TQB2930 and Trastuzumab in HER2-positive breast cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT07047365 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-07-25 and due to reach its primary completion in 2028-06. Interventions recorded: TQB2930+ chemotherapy and Trastuzumab+ chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07047365
- Phase: 3
- Setting: A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT07047365: https://clinicaltrials.gov/study/NCT07047365

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [TQB2930](https://onco.cc/drugs/tqb2930/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07047365.json